ORENCIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORENCIA (ORENCIA).
Selective T cell costimulation modulator; binds to CD80/CD86 on antigen-presenting cells, blocking interaction with CD28 on T cells, thereby inhibiting T cell activation and proliferation.
| Metabolism | Metabolized via peptide hydrolysis; not metabolized by cytochrome P450 enzymes. Clearance occurs primarily through the reticuloendothelial system. |
| Excretion | Primarily eliminated via the reticuloendothelial system through intracellular catabolism; no significant renal or biliary excretion occurs. Fecal excretion is negligible (<0.1%). |
| Half-life | Terminal elimination half-life is approximately 13 days (range 8–25 days) in adults, supporting a once-monthly intravenous dosing regimen. In patients with rheumatoid arthritis, the half-life is consistent across dosing intervals. |
| Protein binding | Approximately 96–98% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.2 L/kg, indicating limited distribution into tissues, consistent with a large monoclonal antibody. |
| Bioavailability | Subcutaneous: Absolute bioavailability is approximately 80% (range 64–100%) compared to intravenous administration. |
| Onset of Action | Intravenous: Clinical improvement may be observed as early as 2 weeks, with maximum effect typically by 8–12 weeks. Subcutaneous: Onset is similar, with steady-state concentrations achieved after 8–12 weeks of weekly dosing. |
| Duration of Action | After a single IV dose, therapeutic effect persists for 4–6 weeks. With repeated dosing, sustained efficacy is maintained; however, discontinuation leads to gradual loss of effect over several weeks to months. |
10 mg/kg intravenously over 30 minutes at weeks 0, 2, and 4, then every 4 weeks thereafter; alternatively, subcutaneous injection: 125 mg once weekly (after a single IV loading dose if transitioning from IV).
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No formal studies in hepatic impairment; no specific dose adjustment recommended. |
| Pediatric use | For juvenile idiopathic arthritis (patients ≥6 years): IV dosing is 10 mg/kg (max 1000 mg) at weeks 0, 2, and 4, then every 4 weeks; subcutaneous dosing: 50 mg (10–25 kg), 87.5 mg (25–50 kg), or 125 mg (≥50 kg) once weekly after a single IV loading dose if needed. |
| Geriatric use | No specific dose adjustment; monitor for infections and tolerability due to higher comorbidity and concurrent medications. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORENCIA (ORENCIA).
| Breastfeeding | No human studies on breast milk excretion. Abatacept is a large protein (IgG1) expected to be present in breast milk at very low concentrations due to molecular size and likely degraded in infant GI tract. M/P ratio not determined. Caution in nursing infants of mothers on therapy, especially premature or immunocompromised infants. |
| Teratogenic Risk | Pregnancy category C. In animal studies, abatacept did not demonstrate teratogenicity at doses up to 29 times the human AUC. Human data are insufficient; monoclonal antibodies like IgG1 cross the placenta increasingly in the second and third trimesters, with highest transfer near term. Potential fetal immune suppression and infection risk, especially B-cell depletion. Avoid use unless benefit outweighs risk. |
■ FDA Black Box Warning
Increased risk of serious infections, including tuberculosis, invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, blastomycosis), and other opportunistic infections. Patients should be tested for latent tuberculosis before initiating therapy. Do not administer with concurrent TNF antagonists; increased risk of infections.
| Serious Effects |
["Concomitant use with a TNF antagonist","Known hypersensitivity to abatacept or any component of the formulation"]
| Precautions | ["Serious infections: screen for tuberculosis and other infections; monitor for signs/symptoms during therapy","Hypersensitivity reactions: anaphylaxis or acute infusion reactions may occur","Concomitant use with other immunosuppressants: increased risk of infections","Vaccinations: avoid live vaccines during therapy","Malignancy: potential increased risk of lymphomas and other malignancies based on animal studies; clinical significance unknown"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal infections, infusion reactions, and immunologic effects. No specific fetal monitoring guidelines; consider serial ultrasound for growth restriction due to underlying maternal disease. Newborns exposed in utero may have altered immune response; avoid live vaccines for 14 weeks after birth or until B-cell count normalized. |
| Fertility Effects | No known direct effects on fertility in humans. Animal studies showed no impairment of fertility at doses up to 29 times human AUC. However, underlying autoimmune disease may affect fertility; disease control may improve reproductive outcomes. |